These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 12139219)
1. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chokejindachai W; Jagsudee A; Saluzzo JF; Bhamarapravati N Am J Trop Med Hyg; 2002 Mar; 66(3):264-72. PubMed ID: 12139219 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632 [TBL] [Abstract][Full Text] [Related]
5. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873 [TBL] [Abstract][Full Text] [Related]
6. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Sun W; Edelman R; Kanesa-Thasan N; Eckels KH; Putnak JR; King AD; Houng HS; Tang D; Scherer JM; Hoke CH; Innis BL Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):24-31. PubMed ID: 14740952 [TBL] [Abstract][Full Text] [Related]
7. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Edelman R; Wasserman SS; Bodison SA; Putnak RJ; Eckels KH; Tang D; Kanesa-Thasan N; Vaughn DW; Innis BL; Sun W Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):48-60. PubMed ID: 14740955 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447 [TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate. Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238 [TBL] [Abstract][Full Text] [Related]
11. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial. George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116 [TBL] [Abstract][Full Text] [Related]
12. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647 [TBL] [Abstract][Full Text] [Related]
13. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Lindow JC; Durbin AP; Whitehead SS; Pierce KK; Carmolli MP; Kirkpatrick BD Vaccine; 2013 Jul; 31(33):3347-52. PubMed ID: 23735680 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225 [TBL] [Abstract][Full Text] [Related]
15. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Sun W; Cunningham D; Wasserman SS; Perry J; Putnak JR; Eckels KH; Vaughn DW; Thomas SJ; Kanesa-Thasan N; Innis BL; Edelman R Hum Vaccin; 2009; 5(1):33-40. PubMed ID: 18670195 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial. Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Wright PF; Ankrah S; Henderson SE; Durbin AP; Speicher J; Whitehead SS; Murphy BR; Pletnev AG Vaccine; 2008 Feb; 26(7):882-90. PubMed ID: 18207289 [TBL] [Abstract][Full Text] [Related]
18. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652 [TBL] [Abstract][Full Text] [Related]
19. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. Durbin AP; Kirkpatrick BD; Pierce KK; Elwood D; Larsson CJ; Lindow JC; Tibery C; Sabundayo BP; Shaffer D; Talaat KR; Hynes NA; Wanionek K; Carmolli MP; Luke CJ; Murphy BR; Subbarao K; Whitehead SS J Infect Dis; 2013 Mar; 207(6):957-65. PubMed ID: 23329850 [TBL] [Abstract][Full Text] [Related]
20. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. Durbin AP; Whitehead SS; Shaffer D; Elwood D; Wanionek K; Thumar B; Blaney JE; Murphy BR; Schmidt AC PLoS Negl Trop Dis; 2011 Aug; 5(8):e1267. PubMed ID: 21829748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]